Business Wire

New Bipolar Disorder Study Shows that a Ketogenic Diet Leads to Mental and Physical Health Benefits

Share

Baszucki Group today announced a new pilot study on a ketogenic diet in bipolar disorder. “For the first time in years, I felt like my brain was finally running on the right fuel,” said one of the study participants. Published today in BJPsych Open, the study is the first to use neuroimaging to demonstrate that a ketogenic diet may improve brain metabolism in individuals with a bipolar disorder diagnosis. With over 100 years of evidence of efficacy in epilepsy, a ketogenic diet is now being studied around the world for a variety of psychiatric and neurological conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211683582/en/

The first-of-its-kind European study, supported by Baszucki Group, used advanced brain imaging techniques, including magnetic resonance spectroscopy (MRS), to measure changes in brain metabolism. The imaging revealed reductions in excitatory neurotransmitters typically elevated in bipolar disorder, suggesting a potential mechanism behind a ketogenic diet's effectiveness. The study also showed that ketone levels correlated with symptom improvement in a subset of individuals who reported daily ratings. This pilot trial points to an important new direction for research and offers hope for innovative treatment options for individuals living with this serious mental illness.

Co-led by University of Edinburgh scientists Iain Campbell, PhD, a Baszucki Metabolic Psychiatry Research Fellow, Daniel Smith, MD, FRCPsych, Chair of Psychiatry, and Harry Campbell, MD, FRSE, FMedSci, the research team enrolled 27 participants with bipolar disorder into a 6-8 week pilot trial of a ketogenic diet. Twenty participants completed the study, demonstrating that the intervention was safe and tolerable in this population. Most reached and maintained ketosis, with 91% of readings positive for blood ketones. Among participants who provided reliable daily ketone and mental health data assessments, increased ketone level was correlated with improvements in mood, energy, impulsivity, and anxiety, with some describing the intervention as life-changing.

“A ketogenic diet gave me a lifeline, restoring my energy and sense of hope,” said a study participant. “I felt like I was finally healing my mind, not just managing my bipolar symptoms. It opened me up to new possibilities and a brighter future.”

“Using a ketogenic diet is like giving my mind a warm bath,” said another participant. “The edginess is gone. I feel calmer, clearer, and my brain is working again.”

Markers of metabolic function also improved. Nineteen of 20 participants lost an average of 9.3 pounds (4.2kg) and saw improvements in body mass index (BMI) and blood pressure. These findings suggest that a ketogenic diet may help mitigate common metabolic health risks associated with bipolar disorder and its pharmacological treatments, which can lead to shortened life spans.

“We observed markers of reduced excitotoxicity in two key brain areas: the anterior cingulate cortex and posterior cingulate cortex—both implicated in bipolar disorder. We also observed effects on a marker which has been associated with Lithium and insulin signaling in the posterior cingulate cortex ” said Dr. Iain Campbell, who also lives with the disorder and follows a ketogenic diet to alleviate his symptoms. “These results add to a small but growing body of evidence suggesting that a ketogenic diet may be an effective adjunctive metabolic intervention for bipolar disorder. There is an urgent need for larger replication studies and carefully designed randomized clinical trials to build on these findings."

These changes align with the metabolic overdrive hypothesis, a theory Drs. Campbell have proposed, which posits that energy dysregulation is central to the mechanism of bipolar disorder and that addressing this dysregulation may be key to the success of ketogenic diet therapy.

A New Frontier in Mental Health

This pilot study paved the way for a broader initiative at the University of Edinburgh, made possible by a competitive research grant from the UKRI Medical Research Council that established the first European Metabolic Psychiatry Hub. The hub, to which Baszucki Group also contributed funding, is a collaboration of over 100 scientists dedicated to accelerating research into the connections between metabolism and mental health. Its focus is to explore the potential of ketogenic therapy and other metabolic interventions for treating severe mental illnesses.

This study is the second recently published pilot trial to demonstrate the safety and potential efficacy of ketogenic therapy in improving both metabolic and mental health markers in serious mental illness. The first trial, also funded by Baszucki Group, was conducted at Stanford University and also suggested that systemic metabolic changes from a ketogenic diet may help stabilize the brain in serious mental illness.

“This trial is another important step forward in establishing ketogenic therapy as a standard treatment for serious mental illness,” said Jan Ellison Baszucki, co-founder and President of Baszucki Group. “We’re proud to have supported this research and remain hopeful that ongoing studies will continue to advance our understanding of the metabolic intervention that saved our son’s life.”

As awareness grows about the deep connection between metabolic function and brain health, this study advances the global scientific movement toward neurometabolic approaches to understanding and treating mental illness.

About Baszucki Group

Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211683582/en/

Contacts

Colby Zintl colby@baszuckigroup.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #

SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &

Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release

Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has

Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 10:28:00 EEST | Press release

Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye